TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled, Open-label, 3-arm Parallel Group, Multi-center Study to Demonstrate Reductions in Exposure to Selected Smoke Constituents in Apparently Healthy Smokers Switching to the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol) or Observing Smoking Abstinence, Compared to Continuing to Use Menthol Conventional Cigarettes, for 5 Days in Confinement and Prolonged by 86 Days in an Ambulatory Setting
Brief Summary: Evaluate if the ad libitum use of the THS 2.2 Menthol (mTHS), a candidate Modified Risk Tobacco Product, for 5 days in confinement, and after 86 days in an ambulatory setting, by apparently adult healthy smokers results in a reduction in the levels of biomarkers of exposure (BoExp) to selected harmful and potentially harmful constituents (HPHCs).


Options:
A: Arm Label: THS 2.2; Type: EXPERIMENTAL; Interventions: Other: THS 2.2 | Arm Label: CC; Type: ACTIVE_COMPARATOR; Interventions: Other: CC | Intervention Type: OTHER; Name: THS 2.2; Assigned to Arm(s): THS 2.2 | Intervention Type: OTHER; Name: CC; Assigned to Arm(s): CC
B: Arm Label: CHTP 1.0; Type: EXPERIMENTAL; Interventions: Other: CHTP 1.0 | Arm Label: Conventional cigarette (CC); Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional Cigarette (CC) | Intervention Type: OTHER; Name: CHTP 1.0; Assigned to Arm(s): CHTP 1.0 | Intervention Type: OTHER; Name: Conventional Cigarette (CC); Assigned to Arm(s): Conventional cigarette (CC)
C: Arm Label: THS 2.2 Menthol (mTHS 2.2); Type: EXPERIMENTAL; Interventions: Other: THS 2.2 Menthol (mTHS 2.2) | Arm Label: Menthol Conventional Cigarette (mCC); Type: ACTIVE_COMPARATOR; Interventions: Other: Menthol Conventional Cigarette (mCC) | Arm Label: Smoking abstinence (SA); Type: SHAM_COMPARATOR; Interventions: Other: Smoking Abstinence (SA) | Intervention Type: OTHER; Name: THS 2.2 Menthol (mTHS 2.2); Assigned to Arm(s): THS 2.2 Menthol (mTHS 2.2) | Intervention Type: OTHER; Name: Menthol Conventional Cigarette (mCC); Assigned to Arm(s): Menthol Conventional Cigarette (mCC) | Intervention Type: OTHER; Name: Smoking Abstinence (SA); Assigned to Arm(s): Smoking abstinence (SA)
D: Arm Label: IQOS; Type: EXPERIMENTAL; Interventions: Device: IQOS | Arm Label: E-CIG; Type: ACTIVE_COMPARATOR; Interventions: Device: E-CIG | Intervention Type: DEVICE; Name: IQOS; Assigned to Arm(s): IQOS | Intervention Type: DEVICE; Name: E-CIG; Assigned to Arm(s): E-CIG

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Chlorhexidine Wipe for Prevention of Multidrug-resistant Organisms in Intensive Care Unit Patients
Brief Summary: The purpose of this study is to determine 2% chlorhexidine wipes are effective in preventing of colonization of multi-drug resistant bacteria in intensive care unit patients.


Options:
A: Intervention Type: PROCEDURE; Name: Bathing with Chlorhexidine Impregnated Washcloths; Assigned to Arm(s): N/A
B: Intervention Type: PROCEDURE; Name: Reinforced isolation + Muciprocine; Assigned to Arm(s): N/A
C: Arm Label: Arm 1: Usual Care-Active Surveillance; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Arm 2: Targeted Decolonization; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine bath and nasal mupirocin | Arm Label: Arm 3: Universal Decolonization; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine bath and nasal mupirocin | Intervention Type: DRUG; Name: Chlorhexidine bath and nasal mupirocin; Assigned to Arm(s): Arm 2: Targeted Decolonization, Arm 3: Universal Decolonization
D: Arm Label: Soap bathing; Type: PLACEBO_COMPARATOR; Interventions: Drug: Soap | Arm Label: 2% chlorhexidine wipes; Type: EXPERIMENTAL; Interventions: Drug: 2% chlorhexidine wipe | Intervention Type: DRUG; Name: 2% chlorhexidine wipe; Assigned to Arm(s): 2% chlorhexidine wipes | Intervention Type: DRUG; Name: Soap; Assigned to Arm(s): Soap bathing

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus
Brief Summary: The purpose of this study is to assess the effect of canagliflozin compared to placebo on progression of albuminuria in participants with Type 2 Diabetes Mellitus receiving standard care but with inadequate glycemic control and at elevated risk of cardiovascular events.


Options:
A: Arm Label: Tight glucose control; Type: EXPERIMENTAL; Interventions: Drug: Insulin | Arm Label: Standard glucose control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Asp(B28)- | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Tight glucose control | Intervention Type: DRUG; Name: Insulin, Asp(B28)-; Assigned to Arm(s): Standard glucose control
B: Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control
C: Arm Label: Empagliflozin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Empagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Empagliflozin; Assigned to Arm(s): Empagliflozin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Canagliflozin (JNJ-28431754); Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin, 100 mg, Drug: Canagliflozin, 300 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Canagliflozin, 100 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754) | Intervention Type: DRUG; Name: Canagliflozin, 300 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus
Brief Summary: The purpose of this study is to assess the effect of canagliflozin compared to placebo on progression of albuminuria in participants with Type 2 Diabetes Mellitus receiving standard care but with inadequate glycemic control and at elevated risk of cardiovascular events.


Options:
A: Arm Label: Semaglutide 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: semaglutide | Arm Label: Semaglutide 1.0 mg; Type: EXPERIMENTAL; Interventions: Drug: semaglutide | Arm Label: Semaglutide placebo 0.5 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Semaglutide placebo 1.0 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: semaglutide; Assigned to Arm(s): Semaglutide 0.5 mg | Intervention Type: DRUG; Name: semaglutide; Assigned to Arm(s): Semaglutide 1.0 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Semaglutide placebo 0.5 mg, Semaglutide placebo 1.0 mg
B: Arm Label: Canagliflozin (JNJ-28431754); Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin, 100 mg, Drug: Canagliflozin, 300 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Canagliflozin, 100 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754) | Intervention Type: DRUG; Name: Canagliflozin, 300 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754)
C: Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: vildagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo of vildagliptin | Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): Vildagliptin | Intervention Type: DRUG; Name: placebo of vildagliptin; Assigned to Arm(s): Placebo
D: Arm Label: Empagliflozin; Type: EXPERIMENTAL; Interventions: Drug: Empagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Empagliflozin; Assigned to Arm(s): Empagliflozin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of Technological Advances to Prevent Smoking Relapse Among Smokers With PTSD
Brief Summary: The primary goal of the study is to evaluate the use of a new smart phone application in preventing relapse to smoking among people with PTSD. The technology intervention will combine a mobile system to reward non-smoking, smoking cessation counseling, smoking cessation medications, and use of the smart phone app. The primary aim is to evaluate how effective this intervention is in preventing smoking relapse compared to another intervention that does not include the app.


Options:
A: Intervention Type: BEHAVIORAL; Name: Smoking Relapse Prevention; Assigned to Arm(s): N/A
B: Arm Label: Longitudinal Care; Type: EXPERIMENTAL; Interventions: Behavioral: smoking cessation | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: smoking cessation | Intervention Type: BEHAVIORAL; Name: smoking cessation; Assigned to Arm(s): Longitudinal Care, Usual Care
C: Arm Label: SBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Behavioral Therapy | Arm Label: CBT; Type: EXPERIMENTAL; Interventions: Behavioral: CBT addressing postpartum mood and weight concerns | Intervention Type: BEHAVIORAL; Name: CBT addressing postpartum mood and weight concerns; Assigned to Arm(s): CBT | Intervention Type: BEHAVIORAL; Name: Supportive Behavioral Therapy; Assigned to Arm(s): SBT
D: Arm Label: QUIT4Ever; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: nicotine replacement therapy, Other: Smoking cessation counseling, Behavioral: mobile contingency management, Other: Stay Quit Coach | Arm Label: Control Contact Condition; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Drug: nicotine replacement therapy, Other: Smoking cessation counseling, Behavioral: mobile contingency management | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Control Contact Condition, QUIT4Ever | Intervention Type: DRUG; Name: nicotine replacement therapy; Assigned to Arm(s): Control Contact Condition, QUIT4Ever | Intervention Type: OTHER; Name: Smoking cessation counseling; Assigned to Arm(s): Control Contact Condition, QUIT4Ever | Intervention Type: BEHAVIORAL; Name: mobile contingency management; Assigned to Arm(s): Control Contact Condition, QUIT4Ever | Intervention Type: OTHER; Name: Stay Quit Coach; Assigned to Arm(s): QUIT4Ever

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of Technological Advances to Prevent Smoking Relapse Among Smokers With PTSD
Brief Summary: The primary goal of the study is to evaluate the use of a new smart phone application in preventing relapse to smoking among people with PTSD. The technology intervention will combine a mobile system to reward non-smoking, smoking cessation counseling, smoking cessation medications, and use of the smart phone app. The primary aim is to evaluate how effective this intervention is in preventing smoking relapse compared to another intervention that does not include the app.


Options:
A: Arm Label: SBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Behavioral Therapy | Arm Label: CBT; Type: EXPERIMENTAL; Interventions: Behavioral: CBT addressing postpartum mood and weight concerns | Intervention Type: BEHAVIORAL; Name: CBT addressing postpartum mood and weight concerns; Assigned to Arm(s): CBT | Intervention Type: BEHAVIORAL; Name: Supportive Behavioral Therapy; Assigned to Arm(s): SBT
B: Arm Label: WhatsApp; Type: EXPERIMENTAL; Interventions: Behavioral: WhatsApp | Arm Label: Facebook; Type: EXPERIMENTAL; Interventions: Behavioral: Facebook | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: WhatsApp; Assigned to Arm(s): WhatsApp | Intervention Type: BEHAVIORAL; Name: Facebook; Assigned to Arm(s): Facebook
C: Arm Label: virtual reality exposure therapy (VRET); Type: EXPERIMENTAL; Interventions: Other: virtual reality exposure treatment | Arm Label: cognitive and behavioral approaches therapy without VRET; Type: EXPERIMENTAL; Interventions: Other: cognitive and behavioral approaches therapy | Intervention Type: OTHER; Name: virtual reality exposure treatment; Assigned to Arm(s): virtual reality exposure therapy (VRET) | Intervention Type: OTHER; Name: cognitive and behavioral approaches therapy; Assigned to Arm(s): cognitive and behavioral approaches therapy without VRET
D: Arm Label: QUIT4Ever; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: nicotine replacement therapy, Other: Smoking cessation counseling, Behavioral: mobile contingency management, Other: Stay Quit Coach | Arm Label: Control Contact Condition; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Drug: nicotine replacement therapy, Other: Smoking cessation counseling, Behavioral: mobile contingency management | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Control Contact Condition, QUIT4Ever | Intervention Type: DRUG; Name: nicotine replacement therapy; Assigned to Arm(s): Control Contact Condition, QUIT4Ever | Intervention Type: OTHER; Name: Smoking cessation counseling; Assigned to Arm(s): Control Contact Condition, QUIT4Ever | Intervention Type: BEHAVIORAL; Name: mobile contingency management; Assigned to Arm(s): Control Contact Condition, QUIT4Ever | Intervention Type: OTHER; Name: Stay Quit Coach; Assigned to Arm(s): QUIT4Ever

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Advance Care Planning by Preparing Diverse Seniors for Decision Making
Brief Summary: The objective of this proposal is to test whether a multi-media website (www.prepareforyourcare.org) that is focused on preparing older adults for communication and medical decision making can help people engage in advance care planning.


Options:
A: Intervention Type: BEHAVIORAL; Name: Patient-Centered Advance Care Planning; Assigned to Arm(s): N/A
B: Arm Label: PREPARE intervention; Type: EXPERIMENTAL; Interventions: Behavioral: PREPARE Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: PREPARE Intervention; Assigned to Arm(s): PREPARE intervention
C: Arm Label: Health Education (HE); Type: EXPERIMENTAL; Interventions: Behavioral: Health Education, Behavioral: Questionnaires, Drug: Nicotine Patches | Arm Label: Motivation and Problem Solving (MAPS); Type: EXPERIMENTAL; Interventions: Behavioral: Health Education, Behavioral: Questionnaires, Behavioral: Telephone Counseling Sessions, Drug: Nicotine Patches | Intervention Type: BEHAVIORAL; Name: Health Education; Assigned to Arm(s): Health Education (HE), Motivation and Problem Solving (MAPS) | Intervention Type: BEHAVIORAL; Name: Questionnaires; Assigned to Arm(s): Health Education (HE), Motivation and Problem Solving (MAPS) | Intervention Type: BEHAVIORAL; Name: Telephone Counseling Sessions; Assigned to Arm(s): Motivation and Problem Solving (MAPS) | Intervention Type: DRUG; Name: Nicotine Patches; Assigned to Arm(s): Health Education (HE), Motivation and Problem Solving (MAPS)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: remote simultaneous medical interpreting | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: usual and customary | Arm Label: 3; Type: OTHER; Interventions: Other: ENglish speaking | Intervention Type: OTHER; Name: remote simultaneous medical interpreting; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: usual and customary; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: ENglish speaking; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Utility of Intensified Case Finding Combined With a Package of Novel TB Diagnostics Using a Mobile Clinic in Africa- a Randomized Controlled Trial (XACT)
Brief Summary: The purpose of this study is to compare two different methods of intensified tuberculosis (TB) case finding in the community. These methods all involve the use of a mobile clinic to reach people with TB symptoms who are not able to readily access clinic services. A standard diagnostics package consisting of smear microscopy and culture (with smear result available the next day) will be compared with a novel diagnostics package involving point-of-care sputum GeneXpert MTB/RIF performed at a mobile or conventional clinic (with same day result), sputum culture, and lateral flow urinary lipoarabinomannan (LAM) testing (in HIV +ve subjects only). The primary outcome is a comparison between the number of culture +ve subjects on TB treatment in each group at the end of two months. A secondary aim is an evaluation of the accuracy and feasibility of GeneXpert performed in a mobile clinic. Additional study aims include using chest X-rays obtained during the study to develop and validate of an computer-aided diagnosis (CAD) software package for TB (together with collaborators in the Netherlands), as well as establishing whether LAM is detectable at sub-ELISA concentrations in the urine of those with TB.


Options:
A: Arm Label: Novel; Type: EXPERIMENTAL; Interventions: Procedure: GeneXpert MTB/RIF assay, Procedure: Smear microscopy | Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Smear microscopy | Intervention Type: PROCEDURE; Name: GeneXpert MTB/RIF assay; Assigned to Arm(s): Novel | Intervention Type: PROCEDURE; Name: Smear microscopy; Assigned to Arm(s): Novel, Standard
B: Arm Label: Standard Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard treatment | Arm Label: Same-Day Treatment Group; Type: EXPERIMENTAL; Interventions: Other: Same-Day Treatment | Intervention Type: OTHER; Name: Same-Day Treatment; Assigned to Arm(s): Same-Day Treatment Group | Intervention Type: OTHER; Name: Standard treatment; Assigned to Arm(s): Standard Group
C: Arm Label: Intervention; Type: OTHER; Interventions: Diagnostic Test: LF-LAM | Arm Label: Standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIAGNOSTIC_TEST; Name: LF-LAM; Assigned to Arm(s): Intervention
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Test-and-Treat Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Test-and-Treat TB | Intervention Type: OTHER; Name: Test-and-Treat TB; Assigned to Arm(s): Test-and-Treat Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Utility of Intensified Case Finding Combined With a Package of Novel TB Diagnostics Using a Mobile Clinic in Africa- a Randomized Controlled Trial (XACT)
Brief Summary: The purpose of this study is to compare two different methods of intensified tuberculosis (TB) case finding in the community. These methods all involve the use of a mobile clinic to reach people with TB symptoms who are not able to readily access clinic services. A standard diagnostics package consisting of smear microscopy and culture (with smear result available the next day) will be compared with a novel diagnostics package involving point-of-care sputum GeneXpert MTB/RIF performed at a mobile or conventional clinic (with same day result), sputum culture, and lateral flow urinary lipoarabinomannan (LAM) testing (in HIV +ve subjects only). The primary outcome is a comparison between the number of culture +ve subjects on TB treatment in each group at the end of two months. A secondary aim is an evaluation of the accuracy and feasibility of GeneXpert performed in a mobile clinic. Additional study aims include using chest X-rays obtained during the study to develop and validate of an computer-aided diagnosis (CAD) software package for TB (together with collaborators in the Netherlands), as well as establishing whether LAM is detectable at sub-ELISA concentrations in the urine of those with TB.


Options:
A: Arm Label: Novel; Type: EXPERIMENTAL; Interventions: Procedure: GeneXpert MTB/RIF assay, Procedure: Smear microscopy | Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Smear microscopy | Intervention Type: PROCEDURE; Name: GeneXpert MTB/RIF assay; Assigned to Arm(s): Novel | Intervention Type: PROCEDURE; Name: Smear microscopy; Assigned to Arm(s): Novel, Standard
B: N/A
C: Arm Label: Urgent ART; Type: EXPERIMENTAL; Interventions: Other: Urgent ART | Arm Label: Early ART; Type: ACTIVE_COMPARATOR; Interventions: Other: Early ART | Intervention Type: OTHER; Name: Urgent ART; Assigned to Arm(s): Urgent ART | Intervention Type: OTHER; Name: Early ART; Assigned to Arm(s): Early ART
D: Intervention Type: DEVICE; Name: Alere "Determine" lateral-flow urine lipoarabinomannan assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Alere "Clearview" ELISA urine LAM assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Cepheid Xpert MTB/Rif assay; Assigned to Arm(s): N/A

Answer: A